Reported results
- Cash, cash equivalents and marketable securities totaled $78.6 million as of September 30, 2026.
- Research and development (R&D) expenses were $21.1 million for the quarter ended September 30, 2026.
- General and administrative (G&A) expenses were $4.7 million for the quarter ended September 30, 2026.
- Loss from operations was $25.8 million for the quarter ended September 30, 2026.
- Net loss was $25.4 million for the quarter ended September 30, 2026.
Guidance
- Cash is expected to support current clinical and operational activities into early 2027.
- The Company expects to report topline results from ALTITUDE-AD in November 2026.
- The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-26 (8-K, Item 2.02). Read the original filing on sec.gov.
